CASI Pharmaceuticals, Inc. Stock price

Equities

CASI

KYG1933S1012

Pharmaceuticals

Delayed Nasdaq 02:05:33 2024-03-28 pm EDT 5-day change 1st Jan Change
3.2 USD +6.67% Intraday chart for CASI Pharmaceuticals, Inc. +4.92% -55.31%
Sales 2023 * 36.42M Sales 2024 * 59.17M Capitalization 39.96M
Net income 2023 * -26M Net income 2024 * - EV / Sales 2023 * 1.1 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.68 x
P/E ratio 2023 *
-1.55 x
P/E ratio 2024 *
-
Employees 224
Yield 2023 *
-
Yield 2024 *
-
Free-Float 51.52%
More Fundamentals * Assessed data
Dynamic Chart
Top Midday Gainers MT
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell MT
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday MT
Top Premarket Gainers MT
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd CI
Casi Pharmaceuticals Announces First Dose of Folotyn in China CI
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer CI
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer CI
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd CI
HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating MT
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q3 Revenue $8.8M MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q2 Revenue $9.8M MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news
1 week-3.54%
Current month-46.33%
1 month-45.26%
3 months-52.76%
6 months+30.43%
Current year-58.10%
More quotes
1 week
2.92
Extreme 2.9201
3.18
1 month
2.92
Extreme 2.9201
6.86
Current year
2.92
Extreme 2.9201
8.19
1 year
1.85
Extreme 1.85
8.48
3 years
1.45
Extreme 1.45
24.20
5 years
1.45
Extreme 1.45
39.00
10 years
1.45
Extreme 1.45
88.92
More quotes
Date Price Change Volume
24-03-28 3.2 +6.67% 81 539
24-03-27 3 0.00% 161,128
24-03-26 3 +0.33% 151,033
24-03-25 2.99 -2.29% 34,201
24-03-22 3.06 +0.33% 20,847

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company's Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3 USD
Average target price
12 USD
Spread / Average Target
+300.00%
Consensus
  1. Stock
  2. Equities
  3. Stock CASI Pharmaceuticals, Inc. - Nasdaq